UBXN11

Across TCGA pan-cancer cohorts, UBXN11 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated UBXN11 data layer compared with 29 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher UBXN11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated UBXN11 expression acts as an unfavorable survival marker.

SCLC, LUAD, and LUSC are the cancer types where UBXN11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.055	0.702	<.001	30	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	12	view →
LUSC	OS	Median	II,III,IV	0.259	0.742	.021	12	view →
SKCM	OS	Median	All	0.249	0.781	.011	12	view →
LIHC	OS	Median	All	0.144	0.688	.013	9	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

UBXN11–SCLC (OS)

Open the SCLC breakdown →